Novavax says COVID-19 vaccine could be approved by year-end

Novavax’s COVID-19 vaccine produced higher levels of neutralising antibodies than produced by recovered patients in an early trial, paving the way for a phase 3 trial and potential approval

Gilead loses $3.3bn in Q2, blaming COVID-19 and cancer drugs...

Gilead has blamed a $3.3 billion loss in Q2 on its acquisition of immune-oncology company Forty Seven – but revenues are declining as the pandemic bit into sales of its hepatitis C drugs.

Understanding COVID-19 and varying responses across the glob...

Imperial's coronavirus vaccine could be available in early 2...

Lockdown is easing across the UK but life is far from the pre-coronavirus “normal” in the absence of a vaccine that has been proven to be safe and effective.

Regeneron begins late-stage trial testing COVID-19 antibody ...

Regeneron has begun a late-stage clinical trial testing its double “antibody cocktail” as a preventive treatment for COVID-19. 

J&J's Ebola vaccine approved in EU

The European Commission has approved Johnson & Johnson's Ebola vaccine, developed by its Janssen pharmaceuticals unit and Bavarian Nordic.